KR102623321B1 - 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체 - Google Patents

중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체 Download PDF

Info

Publication number
KR102623321B1
KR102623321B1 KR1020177025289A KR20177025289A KR102623321B1 KR 102623321 B1 KR102623321 B1 KR 102623321B1 KR 1020177025289 A KR1020177025289 A KR 1020177025289A KR 20177025289 A KR20177025289 A KR 20177025289A KR 102623321 B1 KR102623321 B1 KR 102623321B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177025289A
Other languages
English (en)
Korean (ko)
Other versions
KR20170129729A (ko
Inventor
밀란 치틸
샤론 엥겔
탈린 지 하나니아
바딤 알렉산드로브
에머 레히
Original Assignee
선오비온 파마슈티컬스 인코포레이티드
피지아이 드럭 디스커버리 엘엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 선오비온 파마슈티컬스 인코포레이티드, 피지아이 드럭 디스커버리 엘엘시 filed Critical 선오비온 파마슈티컬스 인코포레이티드
Publication of KR20170129729A publication Critical patent/KR20170129729A/ko
Application granted granted Critical
Publication of KR102623321B1 publication Critical patent/KR102623321B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177025289A 2015-02-11 2016-02-11 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체 Active KR102623321B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115043P 2015-02-11 2015-02-11
US62/115,043 2015-02-11
PCT/US2016/017527 WO2016130790A1 (en) 2015-02-11 2016-02-11 Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

Publications (2)

Publication Number Publication Date
KR20170129729A KR20170129729A (ko) 2017-11-27
KR102623321B1 true KR102623321B1 (ko) 2024-01-09

Family

ID=55456906

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177025289A Active KR102623321B1 (ko) 2015-02-11 2016-02-11 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체

Country Status (21)

Country Link
US (4) US9758529B2 (https=)
EP (3) EP3539967A1 (https=)
JP (4) JP6561128B2 (https=)
KR (1) KR102623321B1 (https=)
CN (2) CN111171047B (https=)
AU (4) AU2016219247B2 (https=)
BR (1) BR112017017349B1 (https=)
CA (1) CA2976092A1 (https=)
DK (1) DK3256476T3 (https=)
EA (1) EA201791802A1 (https=)
ES (1) ES2712627T3 (https=)
IL (2) IL253907B (https=)
MX (1) MX371197B (https=)
NZ (1) NZ734972A (https=)
PH (1) PH12017501423A1 (https=)
PL (1) PL3256476T3 (https=)
PT (1) PT3256476T (https=)
SG (1) SG11201706516WA (https=)
UA (1) UA123262C2 (https=)
WO (1) WO2016130790A1 (https=)
ZA (1) ZA201706074B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111171047B (zh) * 2015-02-11 2023-06-23 赛诺维信制药公司 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
KR101753092B1 (ko) 2016-12-14 2017-07-04 성일하이텍(주) 리튬 함유 폐액으로부터 인산리튬 제조방법
US10850989B2 (en) 2016-12-20 2020-12-01 Sungeel Hitech Co., Ltd. Method for preparing solid lithium salt from lithium solution
CN121221782A (zh) 2017-06-30 2025-12-30 傲拓神经科学公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
WO2019236808A1 (en) 2018-06-07 2019-12-12 Sunovion Pharmaceuticals Inc. Salts of a oxazino[4,3-b]indazole derivative and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
TW202237622A (zh) * 2020-12-04 2022-10-01 美商蘇諾維恩藥業公司 雜環化合物的鹽及其晶型、製備方法、治療用途與醫藥組合物
WO2022217233A1 (en) * 2021-04-08 2022-10-13 Sunovion Pharmaceuticals Inc. Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
EP4416133A1 (en) * 2021-10-11 2024-08-21 Baylor College of Medicine G-protein-coupled receptor regulators and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995052A (en) * 1973-07-09 1976-11-30 Ayerst Mckenna And Harrison Ltd. Indenopyran- and indenothiopyranalkylamines III in the treatment of depression
US4041169A (en) * 1975-03-05 1977-08-09 Ayerst Mckenna And Harrison Ltd. Pharmaceutical method for using pyrano-and thiopyranoindole derivatives
MX2008013053A (es) * 2006-04-12 2008-10-17 Wyeth Corp Derivados de dihidri[1,4]oxazino[2,3,4-hi]indazol-sustituidos como ligandos de 5-hidroxitriptamina-6.
KR20110132564A (ko) * 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
CN106883246B (zh) * 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
CN103313989B (zh) * 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
KR20140082765A (ko) * 2011-10-05 2014-07-02 에프. 호프만-라 로슈 아게 V1a 길항제로서의 사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌
WO2013067248A1 (en) * 2011-11-04 2013-05-10 Vertex Pharmaceuticals Incorporated Benzoxazines as modulators of ion channels
AU2012357169B2 (en) * 2011-12-22 2017-03-30 Merck Patent Gmbh Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
CN104797255A (zh) * 2012-06-20 2015-07-22 范德比尔特大学 作为mglur5受体变构调节剂的取代的双环烷氧基吡唑类似物
JP2014214130A (ja) * 2013-04-26 2014-11-17 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体を含有する医薬
CN111171047B (zh) * 2015-02-11 2023-06-23 赛诺维信制药公司 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物
PL3256466T3 (pl) * 2015-02-11 2022-05-23 Sunovion Pharmaceuticals Inc. Związki 1-heterocykliloizochromanylu i analogi do leczenia zaburzeń oun

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Korneev, S. M. 등, Vestnik Sankt-Peterburgskogo Universiteta, Seriya 4: Fizika, Khimiya, 2009, 제1권, 페이지 155-159

Also Published As

Publication number Publication date
JP2021183624A (ja) 2021-12-02
JP2018505204A (ja) 2018-02-22
BR112017017349B1 (pt) 2024-01-23
CN107567454B (zh) 2020-02-18
IL253907A0 (en) 2017-10-31
EA201791802A1 (ru) 2018-02-28
IL253907B (en) 2020-09-30
IL277658B (en) 2022-03-01
IL277658A (en) 2020-11-30
CN107567454A (zh) 2018-01-09
EP3256476B1 (en) 2019-01-23
PT3256476T (pt) 2019-03-01
MX371197B (es) 2020-01-22
DK3256476T3 (en) 2019-03-11
JP6561128B2 (ja) 2019-08-14
SG11201706516WA (en) 2017-09-28
EP3539967A1 (en) 2019-09-18
JP6928629B2 (ja) 2021-09-01
AU2016219247A1 (en) 2017-09-21
JP2019196385A (ja) 2019-11-14
US20200024286A1 (en) 2020-01-23
ES2712627T3 (es) 2019-05-14
KR20170129729A (ko) 2017-11-27
JP2023036611A (ja) 2023-03-14
AU2016219247B2 (en) 2020-08-13
US9758529B2 (en) 2017-09-12
US20210300942A1 (en) 2021-09-30
US20160264597A1 (en) 2016-09-15
AU2024204310A1 (en) 2024-07-11
NZ734972A (en) 2023-07-28
PL3256476T3 (pl) 2019-05-31
CN111171047B (zh) 2023-06-23
AU2022259828A1 (en) 2022-12-01
EP3256476A1 (en) 2017-12-20
US20180057506A1 (en) 2018-03-01
AU2020267209A1 (en) 2020-12-10
BR112017017349A2 (en) 2018-04-10
MX2017010362A (es) 2018-05-04
EP4006039A1 (en) 2022-06-01
ZA201706074B (en) 2023-05-31
UA123262C2 (uk) 2021-03-10
WO2016130790A1 (en) 2016-08-18
CN111171047A (zh) 2020-05-19
CA2976092A1 (en) 2016-08-18
PH12017501423A1 (en) 2018-03-19
EP4006039B1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
KR102623321B1 (ko) 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
US11491133B2 (en) Heteroaryl-isochroman compounds and uses thereof
KR102601972B1 (ko) 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체
JP2012517471A (ja) ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
HK40073618A (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK40006461A (en) Process for the preparation of fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds
HK40073618B (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK1241875A1 (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK1241875B (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK40078692B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK40078692A (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170908

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230119

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231005

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240105

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240105

End annual number: 3

Start annual number: 1

PG1601 Publication of registration